ANGN - Angion completes enrollment in mid-stage ANG-3777 study for lung injury due to COVID-19

Angion Biomedica (ANGN) has completed enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome, or ARDS. The primary endpoint is survival free from the need for mechanical ventilation or dialysis at 28 days. This trial was powered in a manner where only a very substantial improvement in the primary endpoint will result in a statistically significant outcome. ANG-3777 is an investigational small molecule designed to mimic the biological activity of hepatocyte growth factor, which activates the c-Met cascade of pathways involved in tissue and organ repair.

For further details see:

Angion completes enrollment in mid-stage ANG-3777 study for lung injury due to COVID-19